Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis

Hong, Junshik; Han, Sae‐Won; Ham, Hye Seon; Kim, Tae-Yong; Choi, In Sil; Kim, Byung Su; Oh, Do‐Youn; Im, Seock‐Ah; Kang, Gyeong Hoon; Bang, Yung Jue; Kim, Taeyou

doi:10.1007/s00280-010-1425-7

Cited by 33 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The polymorphism GSTP1 Ile105Val has been predicted to decrease the ability of the cell to defend itself, thus increasing the sensitivity to platinum-based chemotherapy [31,32]. The results of our study showed that GSTP1 105Ile/Val genotype had no significant risk of death when compared with individuals with GSTP1 105Ile/Ile.…”

Section: Discussionsupporting

confidence: 47%

Impact of XRCC1, GSTP1, and GSTM1 Polymorphisms on the Survival of Ovarian Carcinoma Patients Treated with Chemotherapy

Zhai

Huang²,

Wu³

et al. 2016

Oncol Res Treat

View full text Add to dashboard Cite

Background: Single nucleotide polymorphic variants of DNA repair genes may improve drug efficacy through altering expression levels of the encoded proteins. This study evaluated the influence of genetic polymorphism GSTP1 Ile105Val, GSTM1 (null/non-null) and 2 XRCC1 polymorphisms (Arg194Trp and Arg399Gln) on the survival of ovarian carcinoma patients treated with chemotherapy. Methods: 106 patients received treatment with a carboplatin-based or alternative chemotherapy. Polymorphisms were genotyped by pyrosequencing. Results: The genotypes XRCC1 194Arg/Trp and XRCC1 194Trp/Trp conferred no significant risk of death when compared to 194Arg/Arg (hazard ratio (HR) 1.01, 95% confidence interval (CI) 0.33-3.09, and HR 0.89, 95% CI 0.31-2.57, respectively). Similarly, those carrying the XRCC1 399Arg/Gln genotype had no increased risk of death compared to the XRCC1 399Arg/Arg (HR 0.85, 95% CI 0.39-1.86); no homozygous carriers of the glutamine allele (XRCC1 399 Gln/Gln) were detected. The GSTP1 105Ile/Val had no increased risk of death compared to the GSTP1 105Ile/Ile (HR = 1.20, 95% CI = 0.55-2.63) and no homozygous carriers of the valine allele (GSTP1 105Val/Val) were detected in the study. Compared to the non-null genotype of GSTM1, the mortality rate was nonsignificantly reduced in patients with the null genotype (HR 1.07, 95% CI 0.48-2.42). However, overall survival of the patients treated with the carboplatin-based regimen was significantly longer than for those treated with alternative chemotherapy (p_log-rank = 0.006). Conclusions: The present findings suggest that there are no correlations between genotypes and survival.

show abstract

Section: Discussionsupporting

confidence: 47%

Impact of XRCC1, GSTP1, and GSTM1 Polymorphisms on the Survival of Ovarian Carcinoma Patients Treated with Chemotherapy

Zhai

Huang²,

Wu³

et al. 2016

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…GSTP1 is a member of the GST superfamily, and is important in the defense function of cells (28). GSTP1 Ile105Val polymorphism leads to a decreased ability in cell defense, thus increasing the sensitivity of an individual to platinum-based chemotherapy (29,30). However, the results of the Cox proportional hazards regression in the present study revealed no significant association between the GSTP1 Ile105Val isoleucine allele, and no homozygous carriers of the valine allele were detected.…”

Section: Discussioncontrasting

confidence: 54%

Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy

Cong

Zhai

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. The effects of platinum-based drugs are controlled by genes that are involved in DNA detoxification, including glutathione S-transferase (GST)P1 and GSTM1, which have been associated with increased benefits in the chemotherapeutic treatment of patients with ovarian cancer. The present study assessed the effect of single nucleotide polymorphisms in GST genes on the overall survival (OS) of patients with ovarian serous cystadenocarcinoma that were treated with chemotherapy. A total of 95 patients received treatment with a carboplatin-based or alternative chemotherapy. Polymorphisms in the patients were genotyped using the following methods: Pyrosequencing, to identify GSTP1 Ile105Val; a relative quantification method, to identify the copy number variation in GSTM1; and polymerase chain reaction followed by gel electrophoresis, to identify the null vs. non-null genotypes of GSTM1. The association between genotypes and OS of patients was assessed using Kaplan-Meier survival curves and Cox proportional hazards regression analysis. The OS of patients treated with paclitaxel + carboplatin-based chemotherapy was significantly increased, compared with patients treated with alternative forms of chemotherapy (P= 0.035). The OS of patients did not differ significantly between different GSTP1 genotypes (log-rank test, P=0.17). Cox proportional hazards regression analysis revealed that, since the start of the treatment, there was not a significant association between the GSTP1 isoleucine allele and the OS for heterozygous carriers of the isoleucine allele [hazards ratio (HR), 1.78; 95% confidence interval (CI), 0.77-4.12; P=0.18] and no homozygous carriers of the valine allele had been detected (HR, 0.00). There was no significant difference between GSTM1 genotypes, according to Kaplan-Meier survival analysis (log-rank test, P=0.83). Patients that possessed ≤1 copy of GSTM1 exhibited no decrease in OS (HR, 0.96; 95% CI, 0.37-2.51; P=0.94), compared with patients that possessed two copies of GSTM1 (HR, 0.71; 95% CI, 0.22-2.28; P=0.56). Overall, the present results suggest that there are no associations between polymorphisms in the GSTP1 and GSTM1 genes and the OS of patients with ovarian cancer following administration of adjuvant chemotherapy.

show abstract

“…We excluded studies carried out in Asian populations in this discussion as it has been shown that the frequency of GST polymorphisms is different in Asian populations (e.g. dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs =1695) [17,[27][28][29]. Three studies reported no overall association and/or did not investigate the association with chemotherapy [12,13,18].…”

Section: Discussionmentioning

confidence: 99%

Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin

Kap

Richter

Rudolph

et al. 2014

Pharmacogenetics and Genomics

View full text Add to dashboard Cite

show abstract

Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis

Abstract: Biweekly S-1 with oxaliplatin is effective and has improved tolerability and convenience compared to other fluoropyrimidine with oxaliplatin combinations. GSTP1 Ile105Val SNP is associated with treatment outcomes.

Cited by 33 publications

References 27 publications

Impact of XRCC1, GSTP1, and GSTM1 Polymorphisms on the Survival of Ovarian Carcinoma Patients Treated with Chemotherapy

Impact of XRCC1, GSTP1, and GSTM1 Polymorphisms on the Survival of Ovarian Carcinoma Patients Treated with Chemotherapy

Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy

Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin

Contact Info

Product

Resources

About